Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02912260 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by Madrigal Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT02912260 is a Phase 2 study that has completed, run by Madrigal Pharmaceuticals. The registered enrollment target is 125 participants.
The verdict
NCT02912260, a Phase 2 study, has completed, sponsored by Madrigal Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in participants with biopsy-proven Non-alcoholic Steatohepatitis (NASH).
Interventions
- DRUG Placebo
- DRUG MGL-3196
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2016-10-18 |
| Est. Completion | 2021-11-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02912260
The ClinicalTrials.gov registry entry for NCT02912260 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Madrigal Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02912260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02912260 about?
NCT02912260 is a clinical study titled "Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)". The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in participants with biopsy-proven Non-alcoholic Steatohepatitis (NASH).
What is the current status of trial NCT02912260?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2016-10-18. Estimated completion is 2021-11-23.
What interventions are being tested in trial NCT02912260?
The interventions under investigation include: Placebo (DRUG), MGL-3196 (DRUG).
Who is sponsoring clinical trial NCT02912260?
This trial is sponsored by Madrigal Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.